Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma
- 7 February 2012
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 59 (4) , 753-755
Abstract
Arsenic trioxide was tested against the PPTP in vitro panel (1.0 nM to 10 µM) and against the PPTP Ewing sarcoma in vivo panel administered intraperitoneally at a dose of 2.5 mg/kg daily × 5 per week for a planned treatment duration of 3 weeks. Arsenic trioxide showed a median relative IC50 value of 0.9 µM, with Ewing sarcoma cell lines having IC50 values similar to those of the remaining PPTP cell lines. Arsenic trioxide did not induce significant differences in EFS distribution compared to control in any of the Ewing sarcoma xenografts studied, and no objective responses were observed. Pediatr Blood Cancer 2012;59:753–755.Keywords
This publication has 21 references indexed in Scilit:
- From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaBlood, 2011
- Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathwayJournal of Clinical Investigation, 2011
- National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testingPediatric Blood & Cancer, 2010
- Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effectorProceedings of the National Academy of Sciences, 2010
- Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PMLScience, 2010
- A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairmentCancer Chemotherapy and Pharmacology, 2009
- GLI1 Is a Direct Transcriptional Target of EWS-FLI1 OncoproteinJournal of Biological Chemistry, 2009
- Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cellsMolecular Cancer Therapeutics, 2009
- Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphomaBlood, 2008
- Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia PatientsBlood, 1999